Today: 24.Jun.2018
EANM prostate cancer (European Association of Nuclear Medicine) Austria Europe
21.Jul.2017
Rate this item
(0 votes)

European Association of Nuclear Medicine: Prostate cancer patients who are resistant to hormone treatment used to have a poor prognosis. Until recently, the diagnostic and therapeutic possibilities had been limited, but now innovative developments in nuclear medicine imaging and therapy open up promising pathways. Novel substances used with PET/CT (positron-emission tomography combined with computed tomography) not only allow for better diagnosis but also offer treatment options where other therapies have failed.

Read 1372 times Last modified on Thursday, 12 October 2017 12:58

Newsletter Subscription

  • Latest
  • Popular
  • Edgar Ocampo Tellez: El propósito de este…
  • Alexander Hellemans, IEEE Spectrum: As soon as…
  • Vaclav Smil, Czech-Canadian scientist and policy analyst.…
  • IEEE SPECTRUM, The Institute of Electrical and…
  • Nadine Freischlad, writer for Mongabay Series: In…